VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BIOX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BIOXBioceres Crop Solutions Corp.
$0.33$21M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksBIOXBalance Sheet

Bioceres Crop Solutions Corp. (BIOX) Balance Sheet

9Y historyFree accessUpdated daily

The company's financial position appears increasingly vulnerable as the debt-to-equity ratio climbed to 2.25 in 2026Q2, significantly higher than historical levels near 0.75.

BIOX Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMJun'25Jun'24Jun'23Jun'22Jun'21Jun'20Jun'19Jun'18Jun'17
Total Current Assets294.28M308.31M408.67M397.11M297.71M211.49M164.69M98.21M85.34M87.77M
Cash & Short-Term Investments12.58M34.74M56.17M60.05M38.61M46.78M55.96M3.81M2.23M1.68M
Cash Only11.06M32.7M44.47M48.13M33.48M36.05M27.16M3.45M2.22M1.68M
Short-Term Investments1.52M2.04M11.7M11.92M5.14M10.74M28.8M356.23K12.53K4.28K
Accounts Receivable165.84M177.75M216.03M185.32M128.08M99.15M77.84M59.24M52.89M41.68M
Days Sales Outstanding228.28194.66169.64161.26142.33175.08164.85134.87144.61162.33
Inventory67.15M89.99M126.22M140.57M126.1M63.35M30.77M27.59M19.37M31.34M
Days Inventory Outstanding177161.72162.66214.51227.84199.66120.93116.1891.69191.09
Other Current Assets42.36M00212.7K265.12K425.98K128.65K7.36M10.86M12.8M
Total Non-Current Assets266.08M455.33M443.88M420.94M220.52M183.1M132.87M144.26M111.3M152.1M
Property, Plant & Equipment72.06M90.95M86.18M81.79M62.05M49.28M42.63M43.83M40.18M46.22M
Fixed Asset Turnover3.31x3.66x5.39x5.13x5.29x4.19x4.04x3.66x3.32x2.03x
Goodwill36.07M112.16M112.16M112.16M36.07M28.75M25.53M29.8M14.44M25.08M
Intangible Assets87.29M181.17M176.89M173.78M76.7M67.34M35.33M39.62M26.66M42.06M
Long-Term Investments183.63M39.37M40.42M39.74M39.17M31.75M26.35M25.7M19.32M32.88M
Other Non-Current Assets25.66M26.76M18.53M6.15M2.5M2.69M334.73K1.56M5.11M5.87M
Total Assets560.36M763.65M852.55M818.06M518.22M394.59M297.56M242.47M196.64M239.87M
Asset Turnover0.40x0.44x0.55x0.51x0.63x0.52x0.58x0.66x0.68x0.39x
Asset Growth %-58.83%-10.43%4.22%57.86%31.33%32.61%22.72%23.31%-18.02%-
Total Current Liabilities328.64M337.99M329.31M298.71M222.67M168.04M130.61M116.46M118.68M69.39M
Accounts Payable82.54M91.58M161.93M146.29M124.41M69.31M54.79M38.66M26.08M22.28M
Days Payables Outstanding201.52164.58208.67223.23224.77218.42215.37162.78123.48135.86
Short-Term Debt194.42M222M136.75M107.64M71.3M76.79M64.39M66.09M65.03M33.57M
Deferred Revenue (Current)12.97M4.28M3.92M24.88M5.9M6.28M2.87M1.08M1.02M0
Other Current Liabilities33.12M7.94M11.96M5.93M10.67M2.79M2.5M4.49M22.84M7.65M
Current Ratio0.90x0.91x1.24x1.33x1.34x1.26x1.26x0.84x0.72x1.26x
Quick Ratio0.69x0.65x0.86x0.86x0.77x0.88x1.03x0.61x0.56x0.81x
Cash Conversion Cycle203.76191.81123.63152.54145.39156.3370.4188.27112.81217.56
Total Non-Current Liabilities125.11M130.44M171.86M188.85M137.26M136.26M106.9M63.91M44.82M90.74M
Long-Term Debt34.16M38.2M122.91M135.88M86.74M96.65M84.96M36.62M25.25M40.27M
Capital Lease Obligations41.31M9.53M8.16M10.03M10.34M390.41K444.71K462.87K454.26K678.99K
Deferred Tax Liabilities116.28M30.12M35M35.79M29.01M25.7M16.86M21.1M13.59M0
Other Non-Current Liabilities54M51.15M3.86M5.09M11.18M13.52M4.64M5.72M19.12M49.79M
Total Liabilities453.75M468.43M501.17M487.56M359.92M304.3M237.51M180.37M163.51M160.13M
Total Debt239.46M276.61M270.95M257.41M169.79M174.58M149.79M103.56M91.02M74.99M
Net Debt228.39M243.91M226.47M209.28M136.31M138.53M122.63M100.11M88.8M73.31M
Debt / Equity2.25x0.94x0.77x0.78x1.07x1.93x2.49x1.67x2.75x0.94x
Debt / EBITDA12.58x20.20x4.10x3.50x3.46x3.91x3.41x2.81x4.53x19.23x
Net Debt / EBITDA12.00x17.81x3.43x2.84x2.78x3.10x2.79x2.71x4.42x18.80x
Interest Coverage-0.12x-0.08x1.27x2.23x2.16x1.76x1.33x0.57x--
Total Equity106.62M295.22M351.38M330.5M158.3M90.29M60.05M62.09M33.13M79.74M
Equity Growth %-105.08%-15.98%6.32%108.78%75.32%50.37%-3.3%87.41%-58.45%-
Book Value per Share1.684.675.535.233.742.301.652.041.182.84
Total Shareholders' Equity73.77M262.81M315.3M298.85M127.61M67.74M45.48M47.3M13.71M38.34M
Common Stock6.5K6.5K6.5K6.49K4.64K4.16K3.61K3.61K2.81K2.81K
Retained Earnings-255.41M-65.04M-9.63M-13.9M-32.68M-25.48M-18.61M-21.97M-26.15M-15.11M
Treasury Stock-25.17M-32.21M-31.29M-30.55M-3.53M-4.45M-30.91K000
Accumulated OCI61.65K91.81K633.49K1.12M1.98M-27.37M-32.37M-27.22M-28.27M-5.31M
Minority Interest32.85M32.41M36.08M31.65M30.68M22.55M14.57M14.79M19.42M41.4M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Argentine sovereign liquidity constraints

Eroding Equity Base Signals Distress

As reported in recent financial filings, the company's equity base has deteriorated significantly, plummeting from $314.0M in 2024Q4 to just $73.8M by 2026Q2, a trend that reflects the compounding impact of persistent net losses and the erosion of retained earnings over the observed period.

The rapid decline in shareholder equity suggests that the company is struggling to maintain its capital base amidst ongoing operational losses. Investors should monitor whether this trajectory indicates a need for future dilutive financing to stabilize the balance sheet.

Leverage Ratios Reflect Heightened Risk

Based on the latest quarterly data, the debt-to-equity ratio has surged to 2.25 in 2026Q2 from a historical average near 0.75, indicating that the company's reliance on debt financing has intensified precisely as its equity cushion has thinned, warranting close scrutiny of refinancing capabilities.

The sharp increase in leverage appears to be a response to liquidity pressures rather than a strategic capital allocation decision. This shift suggests that the company's debt service capacity may be increasingly constrained by its inability to generate consistent, positive operating cash flows.

Liquidity Buffer Nearing Critical Thresholds

According to the 2026Q2 balance sheet, the current ratio has compressed to 0.90, falling below the critical 1.0 threshold, which implies that the company's short-term assets may no longer be sufficient to cover its immediate liabilities without significant operational or external intervention.

The decline in the current ratio highlights a tightening liquidity environment that leaves little room for error in managing working capital. This trend suggests that the company may face increasing difficulty in meeting its short-term obligations if revenue contraction persists.

Goodwill Impairment Risk Remains Elevated

As indicated by the provided financial data, the company carries $36.1M in goodwill as of 2026Q2, a figure that warrants investigation given the recent 28.3% revenue decline and the potential for future impairment charges to further depress the already fragile equity position.

The presence of significant intangible assets on the balance sheet during a period of operational contraction suggests that the carrying value of past acquisitions may be overstated. Investors should consider the risk that future write-downs could exacerbate the current downward pressure on the company's net worth.

BIOX — Frequently Asked Questions

Quick answers to the most common questions about buying BIOX stock.

What are the total assets of Bioceres Crop Solutions Corp. (BIOX)?

As of 2025, Bioceres Crop Solutions Corp. (BIOX) had total assets of $763.6M including $308.3M in current assets.

How much debt does Bioceres Crop Solutions Corp. (BIOX) have?

Bioceres Crop Solutions Corp. (BIOX) carries total debt of $276.6M, offset by $34.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Bioceres Crop Solutions Corp.?

Bioceres Crop Solutions Corp. (BIOX) has total shareholders' equity (book value) of $262.8M ($4.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Bioceres Crop Solutions Corp.'s current ratio and liquidity?

Bioceres Crop Solutions Corp. (BIOX) reported a current ratio of 0.91x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.